Tafluprost NEW
| Price | $31 | $48 | $74 |
| Package | 2mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-17 |
Product Details
| Product Name: Tafluprost | CAS No.: 209860-87-7 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2026/07/17 |
Product Introduction
Bioactivity
| Name | Tafluprost |
| Description | Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α. |
| In vivo | Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma [3]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 240 mg/mL (530.35 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (22.1 mM), Suspension. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.05 mM), Sonication is recommended. |
| Keywords | Tafluprost | ProstaglandinReceptor | Prostaglandin Receptor | PGF2α | MK-2452 | MK 2452 | Inhibitor | inhibit | AFP168 | AFP 168 |
| Inhibitors Related | Angoroside C | Ufenamate | Pranoprofen | Tranilast | Rutin | Ozagrel | Ethamsylate | Rebamipide | Evodiamine | Lornoxicam | Nepafenac | p-Hydroxycinnamic acid |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:5083-84-1
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-20 | ||
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-07-20 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-20 | ||
| $1.10 |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-06-25 | |
|
airuikechemical co., ltd.
|
2024-12-24 | |||
| $10.00 |
Hebei Ganmiao New material Technology Co., LTD
|
2024-08-20 | ||
|
LY Global chemicals co.,ltd .
|
2023-03-12 | |||
|
Wuhan Godbullraw Chemical Co.,ltd
|
2022-05-18 | |||
|
Wuhan Godbullraw Chemical Co.,ltd
|
2022-05-11 | |||
| $9.90 |
Shanghai Biolang Biotechnology Co., Ltd.
|
2022-02-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY